Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MG, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X, Evert K. Cigliano A, et al. Among authors: evert m, evert k. J Exp Clin Cancer Res. 2022 Jun 3;41(1):192. doi: 10.1186/s13046-022-02394-2. J Exp Clin Cancer Res. 2022. PMID: 35655220 Free PMC article.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, Wang C, Liu Y, Jiang L, Evert K, Demartis MI, Ribback S, Utpatel K, Dombrowski F, Evert M, Calvisi DF, Chen X. Li X, et al. Among authors: evert m, evert k. Oncotarget. 2015 Apr 30;6(12):10102-15. doi: 10.18632/oncotarget.3546. Oncotarget. 2015. PMID: 25826091 Free PMC article.
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X. Zhang S, et al. Among authors: evert m, evert k. J Hepatol. 2017 Dec;67(6):1194-1203. doi: 10.1016/j.jhep.2017.07.006. Epub 2017 Jul 19. J Hepatol. 2017. PMID: 28733220 Free PMC article.
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.
Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X. Dong M, et al. Among authors: evert m, evert k. Cell Death Dis. 2018 Jan 18;9(2):31. doi: 10.1038/s41419-017-0183-4. Cell Death Dis. 2018. PMID: 29348467 Free PMC article.
SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.
Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, Cigliano A, Ribback S, Solinas A, Pes GM, Evert K, Wang H, Song X, Zhang S, Che L, Pascale RM, Calvisi DF, Liu Q, Chen X. Xu M, et al. Among authors: evert k. Cancer Res. 2019 Nov 1;79(21):5563-5574. doi: 10.1158/0008-5472.CAN-18-3750. Epub 2019 Aug 5. Cancer Res. 2019. PMID: 31383647 Free PMC article.
CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X, Kiss A, Schaff Z, Evert K, Zhang Y, Zhong S, Wang J, Evert M, Calvisi DF, Chen X. Chen X, et al. Among authors: evert m, evert k. Pediatr Blood Cancer. 2020 May;67(5):e28221. doi: 10.1002/pbc.28221. Epub 2020 Mar 2. Pediatr Blood Cancer. 2020. PMID: 32124532
The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S, Zhang J, Evert K, Li X, Liu P, Kiss A, Schaff Z, Ament C, Zhang Y, Serra M, Evert M, Chen N, Xu F, Chen X, Tao J, Calvisi DF, Cigliano A. Zhang S, et al. Among authors: evert m, evert k. Am J Pathol. 2020 Jul;190(7):1397-1413. doi: 10.1016/j.ajpath.2020.03.011. Epub 2020 Apr 10. Am J Pathol. 2020. PMID: 32283103 Free PMC article.
RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.
Scheiter A, Evert K, Reibenspies L, Cigliano A, Annweiler K, Müller K, Pöhmerer LM, Xu H, Cui G, Itzel T, Materna-Reichelt S, Coluccio A, Honarnejad K, Teufel A, Brochhausen C, Dombrowski F, Chen X, Evert M, Calvisi DF, Utpatel K. Scheiter A, et al. Among authors: evert m, evert k. Mol Oncol. 2022 Mar;16(5):1091-1118. doi: 10.1002/1878-0261.13135. Epub 2021 Nov 20. Mol Oncol. 2022. PMID: 34748271 Free PMC article.
84 results